Abstract
Aim: Data from two randomized trials were pooled to further characterize the effectiveness of palonosetron combined with dexamethasone in the setting of highly emetogenic chemotherapy. Patients & methods: The analysis included 1411 patients who were randomized to receive palonosetron or ondansetron/granisetron intravenously on day 1 plus either 1-day or 3-day dexamethasone dosing. The primary end point was complete response (no vomiting and no rescue antiemetics over days 1-5) in cycle one. Data across the studies were analyzed by the Mantel-Haenszel method. Results: The vast majority of patients received either cisplatin (62%) or anthracycline plus cyclophosphamide (34%). The palonosetron regimen provided a 12 percentage-point improvement in the rate of overall complete response compared with the control regimen (49.2 vs 37.3%; odds ratio: 1.65; 95% CI: 1.33-2.04; p <0.0001). The frequency of no delayed nausea at all daily periods was consistently higher in the palonosetron group. Conclusion: The current analysis confirmed that palonosetron plus dexamethasone improved control of highly emetogenic chemotherapy-induced nausea and vomiting throughout 5 days postchemotherapy to a significantly greater extent than the combination including older 5-HT3 antagonists.
| Original language | English |
|---|---|
| Pages (from-to) | 1451-1458 |
| Number of pages | 8 |
| Journal | Future Oncology |
| Volume | 9 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2013 |
Fingerprint
Keywords
- chemotherapy-induced nausea and vomiting
- dexamethasone
- highly emetogenic chemotherapy
- nausea
- palonosetron
- vomiting
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Palonosetron plus dexamethasone in highly emetogenic chemotherapy : Pooled data from two Phase III trials. / Celio, Luigi; Agustoni, Francesco; Ricchini, Francesca; Dotti, Katia; Niger, Monica; Braud, Filippo De.
In: Future Oncology, Vol. 9, No. 10, 10.2013, p. 1451-1458.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Palonosetron plus dexamethasone in highly emetogenic chemotherapy
T2 - Pooled data from two Phase III trials
AU - Celio, Luigi
AU - Agustoni, Francesco
AU - Ricchini, Francesca
AU - Dotti, Katia
AU - Niger, Monica
AU - Braud, Filippo De
PY - 2013/10
Y1 - 2013/10
N2 - Aim: Data from two randomized trials were pooled to further characterize the effectiveness of palonosetron combined with dexamethasone in the setting of highly emetogenic chemotherapy. Patients & methods: The analysis included 1411 patients who were randomized to receive palonosetron or ondansetron/granisetron intravenously on day 1 plus either 1-day or 3-day dexamethasone dosing. The primary end point was complete response (no vomiting and no rescue antiemetics over days 1-5) in cycle one. Data across the studies were analyzed by the Mantel-Haenszel method. Results: The vast majority of patients received either cisplatin (62%) or anthracycline plus cyclophosphamide (34%). The palonosetron regimen provided a 12 percentage-point improvement in the rate of overall complete response compared with the control regimen (49.2 vs 37.3%; odds ratio: 1.65; 95% CI: 1.33-2.04; p <0.0001). The frequency of no delayed nausea at all daily periods was consistently higher in the palonosetron group. Conclusion: The current analysis confirmed that palonosetron plus dexamethasone improved control of highly emetogenic chemotherapy-induced nausea and vomiting throughout 5 days postchemotherapy to a significantly greater extent than the combination including older 5-HT3 antagonists.
AB - Aim: Data from two randomized trials were pooled to further characterize the effectiveness of palonosetron combined with dexamethasone in the setting of highly emetogenic chemotherapy. Patients & methods: The analysis included 1411 patients who were randomized to receive palonosetron or ondansetron/granisetron intravenously on day 1 plus either 1-day or 3-day dexamethasone dosing. The primary end point was complete response (no vomiting and no rescue antiemetics over days 1-5) in cycle one. Data across the studies were analyzed by the Mantel-Haenszel method. Results: The vast majority of patients received either cisplatin (62%) or anthracycline plus cyclophosphamide (34%). The palonosetron regimen provided a 12 percentage-point improvement in the rate of overall complete response compared with the control regimen (49.2 vs 37.3%; odds ratio: 1.65; 95% CI: 1.33-2.04; p <0.0001). The frequency of no delayed nausea at all daily periods was consistently higher in the palonosetron group. Conclusion: The current analysis confirmed that palonosetron plus dexamethasone improved control of highly emetogenic chemotherapy-induced nausea and vomiting throughout 5 days postchemotherapy to a significantly greater extent than the combination including older 5-HT3 antagonists.
KW - chemotherapy-induced nausea and vomiting
KW - dexamethasone
KW - highly emetogenic chemotherapy
KW - nausea
KW - palonosetron
KW - vomiting
UR - http://www.scopus.com/inward/record.url?scp=84885676946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885676946&partnerID=8YFLogxK
U2 - 10.2217/fon.13.153
DO - 10.2217/fon.13.153
M3 - Article
C2 - 24106896
AN - SCOPUS:84885676946
VL - 9
SP - 1451
EP - 1458
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 10
ER -